ABVC BioPharma Inc(ABVC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.29 | Insider Own | 18.09% | Shs Outstand | 25.8M | Perf Week | 12.31% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 21.9M | Perf Month | -8.13% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | - | Inst Own | 4.08% | Short Float | 2.24% | Perf Quarter | -8.93% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 5.96% | Short Ratio | 4.69 | Perf Half Y | -8.13% |
| Sales | 0.00B | P/B | 2.62 | EPS next 5Y | - | ROA | -39.88% | Short Interest | 0.49M | Perf YTD | -50.83% |
| Book/sh | 0.4 | P/C | 310.58 | EPS past 3/5Y | 57.67% 39.78% | ROE | -82.15% | 52W High | -65.77% ($3.06) | Perf Year | -62.86% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | -60.78% | 52W Low | 48.15% ($0.71) | Perf 3Y | 14.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -55.9% | Gross Margin | - | Volatility(W/M) | 6.19% 7.13% | Perf 5Y | -95.76% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | -99.71% |
| Dividend Ex-Date | 2013/9/16 | Quick Ratio | 0.07 | EPS Q/Q | 78.2% | Profit Margin | - | RSI (14) | 55.58 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.07 | Sales Q/Q | - | SMA20 | 4.96% ($1) | Beta | 0.46 | Target Price | - |
| Payout | - | Debt/Eq | 0.28 | Earnings | - | SMA50 | 7.49% ($0.98) | Rel Volume | 0.44 | Prev Close | $1 |
| Employees | 19 | LT Debt/Eq | 0.14 | EPS/Sales Surpr. | - | SMA200 | -18.85% ($1.29) | Avg Volume(3M) | 0.10M | Price | $1.05 |
| IPO | 2004/11/10 | Option/Short | Yes/Yes | Trades | 190 | Volume | 45,694 | Change | 4.73% |
ABVC BioPharma is a U.S.- and Taiwan-affiliated biotech company developing <strong>plant-based pharmaceuticals (botanical drugs)</strong> derived from traditional herbal plant ingredients. Its lead pipeline consists of PDC-1421 (an extract of Yuanzhi), a new drug targeting major depressive disorder (MDD) and adult ADHD, and the company is also developing ophthalmic medical devices and oncology pipelines in parallel. Listed on Nasdaq (), it is an early-stage small-cap stock, with licensing revenue serving as the primary source of its sales.
Over the past 1 year, on the lower side
66% below its 1-year high.
Traded less than usual. That is 44% of its average volume.
ABVC has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #456 of 594 in the industry
Based on market cap of $28M.
BCTX#453 BriaCell Therapeutics Corp $30M PER - 
RNAZ#454 TransCode Therapeutics Inc $29M PER - 
CVM#455 Cel-Sci Corp $28M PER - ABVC#456 ABVC BioPharma Inc $28M PER - 
ATOS#457 Atossa Therapeutics Inc $27M PER - 
FAQ
What kind of company is ABVC?
ABVC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ABVC?
The market cap of ABVC is approximately $28M, ranking 5,120 within its sector.
What is the 52-week high and low for ABVC?
ABVC has recorded a 52-week high of $3.06 and a low of $0.71.
